Healthcare IT Today
FEBRUARY 22, 2024
Already worth $350 billion in 2019, the industry is expected to continue increasing given our rapidly aging population and that national healthcare spend is almost 20% of the GDP , as well as the surge in new digital tools, devices, and therapeutics that can drive better patient outcomes.
Health Populi
MAY 20, 2021
to approve Medicare’s negotiation of drug prices with pharmaceutical companies]. Hospitals’ fall from 70% to 63% between 2018 and 2019. Consumer health’s fall from 63% in 2019 to 51% in 2020. The one segment which has stayed relatively even from 2018 has been biotech, 55% that year and 55% again in 2021.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Advanced Medical Reviews
APRIL 17, 2019
Sharpless is a proponent of big data and previously founded two biotech companies. The Center for Medicare & Medicaid Services has posted new data on projected national health expenditures for 2018-2027. percent growth in 2019. CMS Publishes New National Health Expenditures Data.
Health Populi
JANUARY 18, 2019
I’m glad to be getting back to health economic issues after spending the last couple of weeks firmly focused on consumers, digital health technologies and CES 2019. From 2003 to 2019, the theory that prices are the primary driver of America’s spending more on health care than any other country is still the case.
Health Populi
OCTOBER 28, 2019
rank prescription drugs, lab tests, emergency room visits, dental and vision care, preventive services, chronic disease management and mental health care as the “most essential” health care services, according to the 2019 Survey of America’s Patients conducted by The Physicians Foundation. People in the U.S.
Health Populi
MARCH 19, 2019
Key issues facing the industry in 2019 and into the next few years range from regulation of dietary supplements and the role of CBD in self-care, the omni-channel consumer, ecommerce vs. bricks-and-mortar, trust, and wrestling with consumer privacy. Consumer health went opposite, up 7 points, biotech up 3, insurance up 8, pharma up 6.
Health Populi
MAY 8, 2019
In 2018, we saw more incentives to inspire adherence to prescription drug regimens, particularly in Medicare Part D along with increasing focus by pharmacists and providers. For people enrolled in Medicare Part D, 20% faced over $500 in OOP costs. Patients abandon over 20% of new prescriptions when their OOP costs rise above $50.
Expert insights. Personalized for you.
91 
Let's personalize your content